ATC Group: A07DA03 Loperamide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A07DA03 in the ATC hierarchy

Level
Code
Title
1
Alimentary tract and metabolism
2
Antidiarrheals, intestinal antiinflammatory/antiinfective agents
3
Antipropulsives
4
Antipropulsives
5
A07DA03
Loperamide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
10 mg

Active ingredients in A07DA03

Active Ingredient
Description

By binding to opiate receptors in the gut wall, loperamide hydrochloride reduces propulsive peristalsis, increases intestinal transit time and enhances resorption of water and electrolytes. Loperamide increases the tone of the anal sphincter, which helps reduce faecal incontinence and urgency.

Medicines in this ATC group

Drug
Countries

Lithuania

Hong Kong

Ireland

South Africa

Hong Kong Singapore

South Africa

Hong Kong

New Zealand

Hong Kong

New Zealand

France Tunisia

Tunisia

South Africa

Brazil

Singapore

South Africa

United Kingdom

Singapore

Hong Kong

Hong Kong

Australia

Australia New Zealand

South Africa

Tunisia

Finland

Hong Kong

Austria Canada Cyprus Estonia Finland ...

Hong Kong

Austria Brazil

Hong Kong

Brazil

South Africa

Hong Kong

Estonia Finland Germany Lithuania Poland ...

Hong Kong

Hong Kong

Germany Lithuania South Africa

Hong Kong Singapore

Hong Kong Singapore

Hong Kong

South Africa

Hong Kong

Hong Kong Singapore

Hong Kong

Finland

South Africa

Hong Kong

Singapore

Singapore

New Zealand

Hong Kong

Cyprus Hong Kong

New Zealand

South Africa United Kingdom

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Estonia Lithuania

Hong Kong

Hong Kong

Cyprus Hong Kong Singapore

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
CY
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
CY
Summary of Product Characteristics (SPC)
CY